PTC-124, a 1,2,4-oxadiazole compound, is in development by PTC
Therapeutics Inc as an orally active small molecule that can override nonsense stop translation signals to produce full-length
proteins.
PTC-124 is currently being evaluated in phase II clinical trials against
cystic fibrosis (CF) and
Duchenne muscular dystrophy (DMD). The functional properties of
PTC-124 are similar to the
aminoglycoside antibiotic gentamicin, but the two compounds are chemically distinct and
PTC-124 does not exhibit any
antibiotic characteristics. In vitro experiments showed
PTC-124 to be superior to
gentamicin at ribosomal read-through of
nonsense mutations. In vivo investigations revealed that
PTC-124 was effective in restoring the production of full-length
protein in animal models of CF and DMD. Phase I clinical trials reported that
PTC-124 was well tolerated in healthy patients. The author concludes that the encouraging results observed to date make
PTC-124 an attractive option for further well-designed, long-term human studies on larger sample populations. The author also predicts that if results continue to be positive,
PTC-124 could also be trialed in other single gene disorders with
nonsense mutations such as
hemophilia,
neurofibromatosis,
retinitis pigmentosa,
bullous skin diseases and lysosomal storage disorders.